-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235

Benzinga·07/13/2026 11:43:43
語音播報
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.